MaxCyte (NASDAQ:MXCT) Issues Earnings Results

MaxCyte (NASDAQ:MXCT) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04, Zacks reports. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%.

MaxCyte Stock Performance

NASDAQ MXCT traded up $0.05 during trading hours on Tuesday, reaching $3.47. The stock had a trading volume of 563,159 shares, compared to its average volume of 592,048. MaxCyte has a 52-week low of $3.16 and a 52-week high of $5.26. The stock has a market cap of $367.68 million, a P/E ratio of -10.21 and a beta of 1.35. The stock has a fifty day moving average of $4.25 and a 200 day moving average of $4.00.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.